This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundRecent evidence highlights an increasing incidence of myocardialinfarction in young women. years]) admitted to the China Chest Pain Center Database between 2016 and 2021.
Background and aims In the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovasculardiseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor. vs. 53.2%, p = 0.014) and myocardialinfarction (24.7% vs. 5.5.%,
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Patients who had an myocardialinfarction, underwent coronary artery bypass graft (hazard ratio, 1.60 [95% CI, 1.55–1.65]),
With the development of Lp(a)-lowering therapies, this study sought to characterise patterns of Lp(a) levels in a global ASCVD population and identify racial, ethnic, regional and gender differences.
Objective Assessment of generalisability of guideline-informing trials on antithrombotic treatment intensification to real-world patients with cardiovasculardisease (CVD).
clinical success (primary safety and effectiveness) with 100% angiographic success across a broad range of moderate to severe calcium morphologies including eccentric, concentric, and nodular calcifications - - Excellent safety with only one peri-procedural non-Q-wave myocardialinfarction resulting in a 1.7%
Large-scale observational data have demonstrated a robust, independent association of elevated lipoprotein(a) (Lp[a]) levels with atherosclerotic cardiovasculardisease (CVD), stroke, and peripheralarterydisease.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2
In congenital heart diseases, SDoHs can affect major outcomes, as well. In conclusion, SDoHs significantly impact cardiovascular morbidity and death and specific outcomes of patients with cardiovasculardisease.
The study aims to evaluate the applicability in the real world of randomised clinical trials (RCT) on antithrombotic treatment in patients with cardiovasculardisease (CVD) and peripheralarterydisease (PAD).
Introduction Atherosclerotic cardiovasculardisease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The resources use within two years of the diagnosis was estimated in order to estimate the average cost of patient follow-up.
Objective Historical reductions in cardiovasculardisease (CVD) due to lifestyle and treatment improvements are now threatened by factors such as increasing obesity and diabetes, but the relative importance of different risk factors varies by CVD condition.
Published on November 30, 2023, in the Journal of the American College of Cardiology, these new guidelines are based on a comprehensive literature review from May 2022 to November 2022, and provide important recommendations to clinicians caring for patients with or at risk of developing cardiovasculardisease (CVD).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content